Background: The detection of SARS-CoV-2 IgG is important to determine the course of COVID-19. Medical professionals and researchers
have been urging the need for wide and rapid testing of citizens in order to plan measures that can contain the spread of the virus. Antibody tests play
an important role throughout the patient care pathway and are vital for the management and surveillance of the virus. Although RTPCR is
considered to be the gold standard, serological tests based on antibodies could be very helpful for on-time detection. We performed one to one
assessment of electrochemiluminescence immunoassay, enzyme immunoassay (EIAs), and point-of-care lateral ow assay (POCTs) to detect
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibody.
Materials and Methods: 611 healthcare workers were recruited between November and December 2020 at Central Research Laboratory, KIMS.
® Collected serum samples were analysed using three commercially available assays: the Elecsys , Anti-SARS CoV-2 Human IgG ELISA, the
Standard Q IgG/IgM combo assay following the manufacturer's protocol to measure the IgG titer of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2).
Results:The kits displayed a sensitivity of 91.8%, 79.5% ,61.2% and a specicity of 80.2%, 64.1% ,61.7% in order.
Conclusion: ® Our results indicate a high sensitivity and specicity for the Elecsys assay compared to Anti-SARS CoV-2 Human IgG ELISA, the
Standard Q IgG/IgM combo assays.